A novel tumor-promoting mechanism of IL6 and the therapeutic efficacy of tocilizumab: Hypoxia-induced IL6 is a potent autophagy initiator in glioblastoma via the p-STAT3- MIR155-3p -CREBRF pathway

Abstract

Hypoxia induces protective autophagy in glioblastoma cells and new therapeutic avenues that target this process may improve the outcome for glioblastoma patients. Recent studies have suggested that the autophagic process is upregulated in glioblastomas in response to extensive hypoxia. Hypoxia also induces the upregulation of a specific set of proteins and microRNAs (miRNAs) in a variety of cell types. IL6 (interleukin 6), an inflammatory autocrine and paracrine cytokine that is overexpressed in glioblastoma, has been reported to be a biomarker for poor prognosis because of its tumor-promoting effects. Here, we describe a novel tumor-promoting mechanism of IL6, whereby hypoxia-induced IL6 acts as a potent initiator of autophagy in glioblastoma via the phosphorylated (p)-STAT3-MIR155-3p pathway. IL6 and p-STAT3 levels correlated with the abundance of autophagic cells and HIF1A levels in human glioma tissues and with the grade of human glioma, whereas inhibition of exogenous or endogenous IL6 repressed autophagy in glioblastoma cells in vitro. Knockdown of endogenous MIR155-3p inhibited IL6-induced autophagy, and enforced expression of MIR155-3p restored the anti-autophagic activity of IL6 inhibitors. We show that the hypoxia-IL6-p-STAT3-MIR155-3p-CREBRF-CREB3-ATG5 pathway plays a central role in malignant glioma progression, with blockade of the IL6 receptor by tocilizumab demonstrating a certain level of therapeutic efficacy in a xenograft model in vivo, especially in combination with temozolomide. Moreover, tocilizumab inhibits autophagy by promoting tumor apoptosis. Collectively, our findings provide new insight into the molecular mechanisms underlying hypoxia-induced glioma cell autophagy and point toward a possible efficacious adjuvant therapy for glioblastoma patients.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 121

1. 1.

   Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science 2004; 306:990-5; PMID:15528435; http://dx.doi.org/

   Not in our library10.1126/science.1099993

2. 2.

   Thorburn A, Thamm DH, Gustafson DL. Autophagy and cancer therapy. Mol Pharmacol 2014; 85:830-8; PMID:24574520; http://dx.doi.org/

   Not in our library10.1124/mol.114.091850

3. 3.

   Gewirtz DA. The four faces of autophagy: implications for cancer therapy. Cancer Res 2014; 74:647-51; PMID:24459182; http://dx.doi.org/

   Not in our library10.1158/0008-5472.can-13-2966

4. 4.

   Guo JY, Xia B, White E. Autophagy-mediated tumor promotion. Cell 2013; 155:1216-9; PMID:24315093; http://dx.doi.org/

   Not in our library10.1016/j.cell.2013.11.019

5. 5.

   Ichimura Y, Komatsu M. Selective degradation of p62 by autophagy. Semin Immunopathol 2010; 32:431-6; PMID:20814791; http://dx.doi.org/

   Not in our library10.1007/s00281-010-0220-1

6. 6.

   Komatsu M, Ichimura Y. Selective autophagy regulates various cellular functions. Genes Cells 2010; 15:923-33; PMID:20670274; http://dx.doi.org/

   Not in our library10.1111/j.1365-2443.2010.01433.x

7. 7.

   Aredia F, Guaman OLM, Giansanti V, Scovassi AI. Autophagy and cancer. Cells 2012; 1:520-34; PMID:24710488; http://dx.doi.org/

   Not in our library10.3390/cells1030520

8. 8.

   Van Meir E, Sawamura Y, Diserens AC, Hamou MF, de Tribolet N. Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res 1990; 50:6683-8; PMID:2208133

   Not in our library

9. 9.

   Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH, Steiner H, Rumpold H, Fuchs D, Hobisch A, Nemeth JA, et al. The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 2007; 26:2822-32; PMID:17072336; http://dx.doi.org/

   Not in our library10.1038/sj.onc.1210097

10. 10.

    Badache A, Hynes NE. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res 2001; 61:383-91; PMID:11196191

    Not in our library

11. 11.

    Chang KT, Tsai CM, Chiou YC, Chiu CH, Jeng KS, Huang CY. IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol 2005; 289:L446-53; PMID:15894558; http://dx.doi.org/

    Not in our library10.1152/ajplung.00089.2005

12. 12.

    Chang CY, Li MC, Liao SL, Huang YL, Shen CC, Pan HC. Prognostic and clinical implication of IL-6 expression in glioblastoma multiforme. J Clin Neurosci 2005; 12:930-3; PMID:16326273; http://dx.doi.org/

    Not in our library10.1016/j.jocn.2004.11.017

13. 13.

    Tchirkov A, Khalil T, Chautard E, Mokhtari K, Veronese L, Irthum B, Vago P, Kémény JL, Verrelle P. Interleukin-6 gene amplification and shortened survival in glioblastoma patients. Br J Cancer 2007; 96:474-6; PMID:17224923; http://dx.doi.org/

    Not in our library10.1038/sj.bjc.6603586

14. 14.

    Goswami S, Gupta A, Sharma SK. Interleukin-6-mediated autocrine growth promotion in human glioblastoma multiforme cell line U87MG. J Neurochem 1998; 71:1837-45; PMID:9798907; http://dx.doi.org/

    Not in our library10.1046/j.1471-4159.1998.71051837.x

15. 15.

    Liu Q, Li G, Li R, Shen J, He Q, Deng L, Zhang C, Zhang J. IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neurooncol 2010; 100:165-76; PMID:20361349; http://dx.doi.org/

    Not in our library10.1007/s11060-010-0158-0

16. 16.

    Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 2008; 13(Suppl 3):21-6; PMID:18458121; http://dx.doi.org/

    Not in our library10.1634/theoncologist.13-s3-21

17. 17.

    Harris AL. Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2:38-47; PMID:11902584; http://dx.doi.org/

    Not in our library10.1038/nrc704

18. 18.

    Mongiardi MP. Angiogenesis and hypoxia in glioblastoma: a focus on cancer stem cells. CNS Neurol Disord Drug Targets 2012; 11:878-83; PMID:23131159; http://dx.doi.org/

    Not in our library10.2174/1871527311201070878

19. 19.

    Jensen RL. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 2009; 92:317-35; PMID:19357959; http://dx.doi.org/

    Not in our library10.1007/s11060-009-9827-2

20. 20.

    Ji RC. Hypoxia and lymphangiogenesis in tumor microenvironment and metastasis. Cancer Lett 2014; 346:6-16; PMID:24333723; http://dx.doi.org/

    Not in our library10.1016/j.canlet.2013.12.001

21. 21.

    Elstner A, Holtkamp N, von DA. Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells. Clin Exp Metastasis 2007; 24:57-66; PMID:17357815; http://dx.doi.org/

    Not in our library10.1007/s10585-007-9057-y

22. 22.

    Mazure NM, Pouyssegur J. Hypoxia-induced autophagy: cell death or cell survival. Curr Opin Cell Biol 2010; 22:177-80; PMID:20022734; http://dx.doi.org/

    Not in our library10.1016/j.ceb.2009.11.015

23. 23.

    Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132:27-42; PMID:18191218; http://dx.doi.org/

    Not in our library10.1016/j.cell.2007.12.018

24. 24.

    Ohgaki H. Epidemiology of brain tumors. Methods Mol Biol 2009; 472:323-42; PMID:19107440; http://dx.doi.org/

    Not in our library10.1007/978-1-60327-492-0_14

25. 25.

    Ostrom QT, Gittleman H, Stetson L, Virk SM, Barnholtz-Sloan JS. Epidemiology of gliomas. Cancer Treat Res 2015; 163:1-14; PMID:25468222; http://dx.doi.org/

    Not in our library10.1007/978-3-319-12048-5_1

26. 26.

    Davis ME, Stoiber AM. Glioblastoma multiforme: enhancing survival and quality of life. Clin J Oncol Nurs 2011; 15:291-7; PMID:21624864; http://dx.doi.org/

    Not in our library10.1188/11.cjon.291-297

27. 27.

    Sayegh ET, Kaur G, Bloch O, Parsa AT. Systematic review of protein biomarkers of invasive behavior in glioblastoma. Mol Neurobiol 2014; 49:1212-44; PMID:24271659; http://dx.doi.org/

    Not in our library10.1007/s12035-013-8593-5

28. 28.

    McNamara MG, Mason WP. Antiangiogenic therapies in glioblastoma multiforme. Expert Rev Anticancer Ther 2012; 12:643-54; PMID:22594899; http://dx.doi.org/

    Not in our library10.1586/era.12.35

29. 29.

    Raza SM, Fuller GN, Rhee CH, Huang S, Hess K, Zhang W, Sawaya R. Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis. Clin Cancer Res 2004; 10:212-21; PMID:14734472; http://dx.doi.org/

    Not in our library10.1158/1078-0432.ccr-0155-3

30. 30.

    Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, Hammond EH, Devi SN, Kaur B, Van Meir EG. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004; 64:920-7; PMID:14871821; http://dx.doi.org/

    Not in our library10.1158/0008-5472.can-03-2073

31. 31.

    Yuan G, Yan SF, Xue H, Zhang P, Sun JT, Li G. Cucurbitacin I induces protective autophagy in glioblastoma in vitro and in vivo. J Biol Chem 2014; 289:10607-19; PMID:24599950; http://dx.doi.org/

    Not in our library10.1074/jbc.m113.528760

32. 32.

    Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004; 117:1281-3; PMID:15020666; http://dx.doi.org/

    Not in our library10.1242/jcs.00963

33. 33.

    Luwor RB, Stylli SS, Kaye AH. The role of Stat3 in glioblastoma multiforme. J Clin Neurosci 2013; 20:907-11; PMID:23688441; http://dx.doi.org/

    Not in our library10.1016/j.jocn.2013.03.006

34. 34.

    Greenhill CJ, Rose-John S, Lissilaa R, Ferlin W, Ernst M, Hertzog PJ, Mansell A, Jenkins BJ. IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. J Immunol 2011; 186:1199-208; PMID:21148800; http://dx.doi.org/

    Not in our library10.4049/jimmunol.1002971

35. 35.

    Groner B, Lucks P, Borghouts C. The function of Stat3 in tumor cells and their microenvironment. Semin Cell Dev Biol 2008; 19:341-50; PMID:18621135; http://dx.doi.org/

    Not in our library10.1016/j.semcdb.2008.06.005

36. 36.

    Cao Q, Li YY, He WF, Zhang ZZ, Zhou Q, Liu X, Shen Y, Huang TT. Interplay between microRNAs and the STAT3 signaling pathway in human cancers. Physiol Genomics 2013; 45:1206-14; PMID:24192393; http://dx.doi.org/

    Not in our library10.1152/physiolgenomics.00122.2013

37. 37.

    Wan G, Xie W, Liu Z, Xu W, Lao Y, Huang N, Cui K, Liao M, He J, Jiang Y, et al. Hypoxia-induced MIR155 is a potent autophagy inducer by targeting multiple players in the MTOR pathway. Autophagy 2014; 10:70-9; PMID:24262949; http://dx.doi.org/

    Not in our library10.4161/auto.26534

38. 38.

    Audas TE, Li Y, Liang G, Lu R. A novel protein, Luman/CREB3 recruitment factor, inhibits Luman activation of the unfolded protein response. Mol Cell Biol 2008; 28:3952-66; PMID:18391022; http://dx.doi.org/

    Not in our library10.1128/mcb.01439-07

39. 39.

    Lu R, Yang P, O'Hare P, Misra V. Luman, a new member of the CREB/ATF family, binds to herpes simplex virus VP16-associated host cellular factor. Mol Cell Biol 1997; 17:5117-26; PMID:9271389; http://dx.doi.org/

    Not in our library10.1128/mcb.17.9.5117

40. 40.

    Mori K. Tripartite management of unfolded proteins in the endoplasmic reticulum. Cell 2000; 101:451-4; PMID:10850487; http://dx.doi.org/

    Not in our library10.1016/s0092-8674(00)80855-7

Cited by papers we hold 9

• Epigenetic and post-translational modifications in autophagy: biological functions and therapeutic targets · 2023
  No notice
• The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies · 2022
  No notice
• ELK3: A New Molecular Marker for the Diagnosis and Prognosis of Glioma · 2021
  Not checked
• Hypoxic glioma-derived exosomes promote M2-like macrophage polarization by enhancing autophagy induction · 2021
  No notice
• Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment · 2020
  No notice
• The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment · 2020
  No notice
• Overexpression of Limb-Bud and Heart (LBH) promotes angiogenesis in human glioma via VEGFA-mediated ERK signalling under hypoxia · 2019
  Not checked
• Autophagy and inflammation · 2017
  No notice
• Autophagy-Regulating microRNAs and Cancer · 2017
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.